Kratom-containing dietary supplement manufacturers and marketers are asking FDA to recant its Nov. 14 consumer advisory about the ingredient, arguing the agency's information is inaccurate and casting the ingredient as a tool in helping curb narcotics abuse.
Kratom Supplement Marketers Dispute FDA Warning, Ask For Review
In addition to a review of the advisory announced by FDA Commissioner Gottlieb, a trade group petitions the agency for a meeting to allow stakeholders "to correct misstatements and factual errors on the science regarding the safety and addiction potential of kratom."
